Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's Letairis Gets Boost Against Actelion's Tracleer With Removal Of Liver Warning

This article was originally published in The Pink Sheet Daily

Executive Summary

REMS helps drive the endothelin receptor antagonist to a cleaner label, as the pulmonary arterial hypertension drug's black box will be modified and liver testing requirements dropped.

You may also be interested in...

Chantix's Boxed Warning: Will A Positive Vote Justify A Negative Outcome?

FDA could use advisory committee members' comments to maintain the smoking cessation drug's boxed warning, even though they voted to remove it.

Actelion Defends PAH Franchise With Generics And Second-Generation Drugs

With patent erosion starting for Tracleer, its largest-selling product, Actelion outlines further details of its short- and medium-term strategy to reduce its reliance on the billion-dollar PAH therapy.

Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer

CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts